Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiotepa + busulfan + fludarabine + cytarabine
- Development stage
- Unknown
- Lead developer
- Xianmin Song, MD
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
thiotepa + busulfan + fludarabine + cytarabine is a reduced-intensity conditioning (RIC) regimen being investigated for use in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This combination therapy, evaluated in a Phase II clinical trial led by Xianmin Song, MD, at the Shanghai General Hospital, aims to provide effective lymphodepletion and myeloablation with reduced toxicity compared to standard high-dose conditioning. The regimen's mechanism involves the synergistic action of DNA alkylating agents (thiotepa and busulfan) which cause DNA cross-linking, and antimetabolites (fludarabine and cytarabine) which inhibit DNA synthesis and repair mechanisms. The primary goal of this specific RIC protocol is to improve progression-free survival (PFS) and overall survival (OS) in the PTCL patient population.
- Other names
- RIC with Thiotepa Combined With Bu/Flu/Ara-CThiotepa-Bu-Flu-Ara-C regimenthiotepa-Xianmin Song, MD-peripheral T-cell lymphoma
02
Targets
POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on thiotepa + busulfan + fludarabine + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thiotepa + busulfan + fludarabine + cytarabine.